Fig. 5: LSC47 risk stratification model. | Nature Communications

Fig. 5: LSC47 risk stratification model.

From: Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia

Fig. 5

a To build a robust risk prediction model for pediatric AML, we aggregated LSC47 based signatures with other validated biomarkers (e.g., RUNX1-RUNX1T1 transcriptional signature and CBFB-MYH11 fusion breakpoint location) within our training cohort. NUP98 partner fusion and CBFA2T3-GLIS2 AMLs are associated with 5-year EFS of < 20% and were therefore assigned to the high-risk stratum without further stratification. Kaplan–Meier estimates for the probability of EFS based on b cytomolecular (CM) risk factors, c LSC17, and d, e combined LSC47 model in training and validation cohorts. Survival differences were determined using the log-rank test (two-sided and without multiple-testing adjustments).

Back to article page